CTC: Cognitive Training for Older Caregivers

Sponsor
University of Rochester (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03036423
Collaborator
National Institute on Aging (NIA) (NIH)
240
1
2
75
3.2

Study Details

Study Description

Brief Summary

The purpose of this study is to test whether certain brain training activities can promote cognitive, emotional, and physical health in caregivers of a loved one with dementia. Numerous studies show that family dementia caregiving can be stressful, and can increase mental and physical health risks. This study aims to understand how to reduce those risks.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Online video education
  • Behavioral: Computerized mental exercises
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Cognitive Training to Protect Immune Systems of Older Caregivers
Study Start Date :
Sep 1, 2016
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Online video education

Participants will have computer access to a library of videos, including various lectures and demonstrations of interest, from which to select and view.

Behavioral: Online video education

Active Comparator: Computerized mental exercises

Participants will use a computer to do a variety of activities which are customizable to their own abilities and progress.

Behavioral: Computerized mental exercises

Outcome Measures

Primary Outcome Measures

  1. Useful Field of View test performance at 12 months after the intervention [12 months after the intervention]

    Useful Field of View computerized test of speed of processing and attention; lower score (in milliseconds) reflects better performance

  2. Resting high frequency heart rate variability (HF-HRV) at 12 months after the intervention [12 months after the intervention]

    HF-HRV is derived by spectral analysis of the electrocardiograph (ECG) waveform and is a measure of parasympathetic control of the heart; Higher resting HF-HRV (in Hz) reflects greater parasympathetic regulation of the heart

  3. Emotion regulation at 12 months after the intervention [12 months after the intervention]

    Measured as change in negative affect (from responses to the self-assessment manikin on a 9-point scale) from before to after a mental challenge; less increase in negative affect score suggests better emotion regulation

  4. Emotional well-being at 12 months after the intervention [12 months after the intervention]

    The primary index of emotional well-being will be depressive symptoms (Center for Epidemiology Studies Depression scale); a lower score on this measure indicates less depressive symptoms

  5. Immune aging [12 months after the intervention]

    Identified from blood samples; lower levels of inflammation (measured by enzyme-linked immunosorbent assay (ELISA) assay) and T-lymphocyte profiles that reflect larger ratios of naïve T-cells relative to mature T-cells (measured from flow cytometry) will index less aging of the immune system

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • English-speaking (consent process and assessments will be conducted in English only)

  • Currently living with or in proximity to, and the primary caregiver for a loved one with dementia who lives in the community-for the purposes of this study, "loved one" refers to a family member such as a spouse, ex-spouse, significant other, sibling, in-law, parent, or other type of close established relationship (e.g., close friend) regarded as family; "primary caregivers" provide daily informal (non-paid) in-person care.

  • Currently experiencing moderate to high levels of perceived stress and caregiver burden. Caregivers will be screened for stress levels and caregiving burden using the 10-item Perceived Stress Scale (PSS 10) and the Modified Caregiver Strain Index (MCSI), respectively. Caregivers scoring above the population mean (approx.) on the PSS 10 (> 11), reporting at least moderate caregiver strain (score ≥ 5) on the MCSI will be eligible for participation.

Exclusion Criteria:
  • cognitive impairment or dementia (identified by the Montreal Cognitive Assessment (MoCA)). Cutoff scores on the MoCA will be 23 or lower except for subjects who identify as black or African American, in which case cutoffs will be based on scores from the sample population reported in Rossetti et al (2017); subjects scoring greater than one standard deviation below the published score, by respective age and education, will be excluded.

  • current major depression (current Major Depression diagnosis and/or Geriatric Depression Scale (GDS 15) score ≥ 10)

  • no recent (within 2 months) major surgery

  • History of events that cause neurological injury (e.g., stroke, transient ischemic attack, traumatic brain injury or head injury with loss of consciousness)

  • Serious psychiatric or alcohol/substance use disorders, including current alcohol dependence, current non-alcohol psychoactive substance use dependence, psychotic disorders or features (current and lifetime), bipolar disorder (determined from Mini International Neuropsychiatric Exam (MINI) modules)

  • Autoimmune disorder (e.g., Crohn's disease, lupus, rheumatoid arthritis)

  • Active neoplastic disease or receiving immunosuppressive therapy for cancer (or < 6 months post-chemo or radiation) or other diseases (< 3 months prior to enrollment)

  • No significant immunodeficiency disorder (e.g., alymphocytosis, hepatitis B or C, HIV)

  • Serious cardiovascular disease (e.g., congestive heart failure, pacemaker) or myocardial infarction within past 6 months

  • Physical condition precluding required activities as part of the computerized cognitive training (e.g., inability to use a computer mouse; inadequate visual acuity)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Rochester Medical Center Rochester New York United States 14642

Sponsors and Collaborators

  • University of Rochester
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Kathi L Heffner, PhD, University of Rochester

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kathi Heffner, Associate Professor of Nursing and Psychiatry, University of Rochester
ClinicalTrials.gov Identifier:
NCT03036423
Other Study ID Numbers:
  • STUDY0001991
  • R01AG049764
First Posted:
Jan 30, 2017
Last Update Posted:
Aug 17, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 17, 2022